

ONCOLOGY RELATED DRUGS WITH SPECIAL ORDERING PROCESS

Primary Drug Name	Alternate Drug Names	Supplier	BC Cancer Benefit	Health Canada NOC	Comments
AGS-16C3F		Astellas Pharma USA Tel: 1-224-205-8279	No	No	Health Canada Special Access Request Form A and manufacturer approval
Alemtuzumab	MABCAMPATH	Genzyme Tel: 905-267-3184 MabCampath Distribution Program managed by Clinigen Group www.clinigengroup.com Tel: +44 1283 494340 Fax: +44 1283 494341 Email: customer.services@clinigengroup.com	Yes	No	<ul style="list-style-type: none"> Contact Clinigen Group to open an account – company will send a Clioport registration form Complete Clioport Registration form with email address for authorizing physician(s) and pharmacist(s) placing the order via Clioport, fax to +44 1283 494341 Once registered, company will send guidance on using Clioport portal for ordering, tracking orders, reassigning vials, and closing out patients records Reports detailing all shipments and current status of Campath can be downloaded through Clioport portal
Alisertib		Takeda	No	No	Health Canada Special Access Request Form A and manufacturer approval
Anlotinib		Advenchen	No	No	Health Canada Special Access Request Form A and manufacturer approval
Asparaginase-erwinia	ERWINASE	CGF Pharmatech Tel: 1-866-343-0344	Yes	Cancelled	Health Canada Special Access Request Form A and manufacturer approval
Avapritinib	AYVAKIT	Wep Clinical vrodriques@wepclinical.com	No	No	Health Canada Special Access Request Form A and manufacturer approval
Belantamab mafodotin	GSK2857916	GSK Tel: +44 20 8047 4856	No	No	Health Canada Special Access Request Form A and manufacturer approval
Belinostat	BELEODAQ	Servier Canada Tel: 450-978-0409 #4381	No	No	Health Canada Special Access Request Form A and manufacturer approval
Belzutifan	WELIREG	Merck	No	No	Health Canada Special Access Request Form A and manufacturer approval
Bexarotene	TARGRETIN	Valeant Pharmaceuticals Tel: 1-800-361-4261 Email: medinfo_canada@valeant.com	Yes	No	Health Canada Special Access Request Form A and manufacturer approval
Capmatinib	TABRECTA	Novartis Canada Fax 1-416-262-4992 Email: Adrian.gunaratne@novartis.com	No	Yes	Now marketed
Cediranib		Astra Zeneca Tel: 1-800-565-5877 Email: sapcanadaastrazeneca@astrazeneca.com	No	No	Health Canada Special Access Request Form A and manufacturer approval

ONCOLOGY RELATED DRUGS WITH SPECIAL ORDERING PROCESS

Primary Drug Name	Alternate Drug Names	Supplier	BC Cancer Benefit	Health Canada NOC	Comments
Cytarabine liposomal	DEPOCYT	Sigma-Tau Rare dedication Support Centre, US Tel: 1-888-276-2217 Fax: 1-866-489-1898	No	No	Discontinued by manufacturer (May2018)
Daunorubicin liposomal	DaunoXome	GALEN PHARMA (UK) Tel: 02838334974 Email: snavani@galen.co.uk	No	No	Health Canada Special Access Request Form A and manufacturer approval
Denileukin diftiox	ONTAK	Ligand Pharmaceuticals Tel: 1-508-435-8484 x 353	No	No	Health Canada Special Access Request Form A and manufacturer approval
Etoposide phosphate	ETOPOPHOS	Xedition Tel: 905-286-9111	No	No	Health Canada Special Access Request Form A and manufacturer approval

ONCOLOGY RELATED DRUGS WITH SPECIAL ORDERING PROCESS

Primary Drug Name	Alternate Drug Names	Supplier	BC Cancer Benefit	Health Canada NOC	Comments
Glucarpidase	Carboxypeptidase-G2, CPDG2, VORAXAZE	McKesson Canada Tel: 1-877-384-7425	No	No	<p>Requires approval at regional centre level. No CAP required, has drug cost. Health Canada Special Access Request Form A Needs urgent Health Canada approval:</p> <ul style="list-style-type: none"> • Fax completed form to SAP and call ahead to SAP at 613-941-2108 • Confirm with SAP that request is urgent and inform them on patient status. SAP can approve request within 10 minutes if all sections on the form are complete. • SAP faxes Letter of Approval (LOA) to McKesson. • McKesson delivers drug within 24 h of receiving LOA. <p>If request is after hours:</p> <ul style="list-style-type: none"> • Physician calls directly to SAP at 613-941-2108 for authorization. • SAP calls McKesson. • McKesson ships drug within 24 h. <p>Eligibility Criteria: Patients receiving High Dose Methotrexate Protocols who develop MTX toxicity due to delayed elimination. Patients must have:</p> <ul style="list-style-type: none"> • MTX level does not decrease to expected below 5×10^{-2} micromol/L after 48 h, despite leucovorin rescue, AND • Deteriorating renal function <p>Dose: 50 units/kg IV; for MTX level above 100 micromol/L may give second dose 48 h after first dose. See Cancer Drug Manual MTX monograph for more dosing information.</p>
Hyaluronidase	AMPHADASE	Amphastar Pharmaceuticals Inc Tel: 1-800-423-4136	No	Cancelled	Standard item in BC Cancer extravasation kits. No CAP required for extravasation, has drug cost. Health Canada Future Use Request Form B
Iniparib		sanofi-aventis Tel: 1-800-363-6364, 1-800-265-7927 Email: Helene.Grassin@sanofi-aventis.com	No	No	Health Canada Special Access Request Form A and manufacturer approval

ONCOLOGY RELATED DRUGS WITH SPECIAL ORDERING PROCESS

Primary Drug Name	Alternate Drug Names	Supplier	BC Cancer Benefit	Health Canada NOC	Comments
Ipatasertib		Roche Tel: 905-542-5826	No	No	Health Canada Special Access Request Form A and manufacturer approval
Ivosidenib		Agios Tel: 862-222-5542	No	No	Health Canada Special Access Request Form A and manufacturer approval
Ixabepilone	IXEMPRA	R-Pharm US	No	No	Health Canada Special Access Request Form A and manufacturer approval
Mafosfamide		Asta Medica Germany Tel: 011-4969-40012887	No	No	Health Canada Special Access Request Form A and manufacturer approval
Mechlorethamine injectable	MUSTARGEN	Recordati Rare Disease (USA) Tel: 847-205-5503	No	Cancelled	Discontinued by manufacturer (31Dec2018)
Mobocertinib	TAK-788	Association of Reproductive Health Professionals Tel: 202-466-3825 Fax: 202-466-2826	No	No	Health Canada Special Access Request Form A and manufacturer approval
Mogamulizumab	POTELIGEO	Takeda Canada Tel: 1-844-884-4968	No	No	Health Canada Special Access Request Form A and manufacturer approval
Nimorazole	NIMORAZOLE	Azanta 1-647-968-9887 Chia Chia Sun: ccs@azanta.com	No	No	Health Canada Special Access Request Form A and manufacturer approval
Nimotuzumab		<ul style="list-style-type: none"> • YM BIOSCIENCES 905-629-9761 • Calea (drug distribution) 888-865-5372 • website www.nimotuzumab-access.com 	No	No	Health Canada Special Access Request Form A and manufacturer approval
Nirogacestat		SpringWorks therapeutics Medinfo@springworksstx.com	No	No	Health Canada Special Access Request Form A and manufacturer approval
Ofatumumab	ARZERRA	GlaxoSmithKline Tel: 1-800-387-7374 Fax: 1-800-565-2935 Email: cacsu@gsk.com	No	Cancelled	Compassionate request for chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab
Panobinostat		Novartis email: medinfo.canada@novartis.com Tel: 1-800-363-8883	No	No	Health Canada Special Access Request Form A and manufacturer approval
Pentostatin		Pfizer Canada Tel: 514-426-7487	No	Cancelled	Health Canada Special Access Request Form A and manufacturer approval
REOLYSIN®		Oncolytics Biotech Tel: 403-670-7377 Fax: 403-283-0858	No	No	Health Canada Special Access Request Form A and manufacturer approval
Sargramostim	LEUKINE, GMCSF	SANOFI Tel: 1-800-265-7927	Yes	No	Health Canada Special Access Request Form A and manufacturer approval

ONCOLOGY RELATED DRUGS WITH SPECIAL ORDERING PROCESS

Primary Drug Name	Alternate Drug Names	Supplier	BC Cancer Benefit	Health Canada NOC	Comments
Selinexor		Karyopharm Therapeutics Tel: 1-917-485-1209	No	No	Health Canada Special Access Request Form A and manufacturer approval
Selitrectinib		Bayer www.bayer.ca	No	No	Not available via SAP (16Feb2021)
Selumetinib	AZD6244	AstraZeneca	No	No	Not available via SAP
Sirolimus-nab	ABI-009	Bionical-emas 1-888-346-8672	No	No	Health Canada Special Access Request Form A and manufacturer approval
Streptozocin	ZANOSAR	KEOCYT, France, www.keocyt.com Tel: +33 (0)1 42 31 07 10 Email: ivan.hagay@keocyt.com	Yes	Cancelled	Health Canada Special Access Request Form A and manufacturer approval
Tazemetostat	EZH-701	Epizyme Tel: 1-910-364-7803 Email: jgilchrist@wepclinical.com	No	No	Health Canada Special Access Request Form A and manufacturer approval
Tebentafusp	KIMMTRAK	Immunocore	No	No	Health Canada Special Access Request Form A and manufacturer approval
Tislelizumab	BGB-A317	Geigene Tel: 628-239-0631	No	No	Health Canada Special Access Request Form A and manufacturer approval
Tomivosertib	eFT508	effECTOR Therapeutics	No	No	Health Canada Special Access Request Form A and manufacturer approval
Toremifene	FARESTON	Orion Pharma Tel: +358-10-426-4416 Email: paula.rytila@orionpharma.com	No	No	Not available via SAP
Uridine triacetate	VISTOGARD, Vistonuridine	Wellstat Therapeutics Tel: 800-914-0071 Michael Bamat, PhD: mbamat@wellstat.com	No	No	Requires approval at regional centre level. No CAP required, no cost for drug, cost for shipping. Emergency line: 800-914-0071 Monitored 24 hours a day, 7 days a week. Call ASAP after overdose or after early-onset severe toxicity is recognized. Health Canada Special Access Request Form A and manufacturer approval.
Vincristine liposomal	VSLI	Inex Pharmaceutical Corporation Tel: 604-419-3211	No	No	Health Canada Special Access Request Form A and manufacturer approval

SAP = Special Access Program, NOC = Notice of Compliance

Health Canada Special Access Request Form <http://www.hc-sc.gc.ca/dhp-mps/acces/drugs-drogués/index-eng.php>